Interaction of rifalazil with oxidant-generating systems of human polymorphonuclear neutrophils

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 12, 2005, Pages 5018-5023

  Labro, M T ^a   Ollivier, V ^a   Babin Chevaye, C ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANSAMYCIN DERIVATIVE; ANTIINFLAMMATORY AGENT; CYTOCHROME C; DICHLORODIHYDROFLUORESCEIN DIACETATE; FORMYLMETHIONYLLEUCYLPHENYLALANINE; HYPOXANTHINE; IMMUNOSUPPRESSIVE AGENT; LUCIGENIN; OXIDIZING AGENT; OXYGEN; PHORBOL 13 ACETATE 12 MYRISTATE; RIFALAZIL; RIFAMPICIN; XANTHINE OXIDASE;

ANTIOXIDANT ACTIVITY; ARTICLE; CHEMOLUMINESCENCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CROSS REACTIVITY; DRUG POTENCY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; INFLAMMATION; LIGHT; NEUTROPHIL; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; CELL SURVIVAL; HUMANS; NEUTROPHILS; OXIDANTS; REACTIVE OXYGEN SPECIES; RIFAMYCINS; SUPEROXIDES;

EID: 28844488217     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.12.5018-5023.2005     Document Type: Article

References (31)

1. Afanas'ev, I. B., E. A. Ostrachovitch, and L. G. Korkina. 1999. Lucigenin is a mediator of cytochrome c reduction but not of superoxide production. Arch. Biochem. Biophys. 366:267-274.
2. Aniansson, H., O. Stendhal, and C. Dahlgren. 1984. Comparison between luminol- and lucigenin-dependent chemiluminescence of polymorphonuclear leukocytes. Acta Pathol. Microbiol. Immunol. Scand. Sect. C 92:357-361.
3. Bermudez, L. E., and C. B. Inderlied. 1997. Effect of Mycobacterium avium infection on the influx, accumulation, and efflux of KRM-1648 by human macrophages. Microb. Drug Resist. 3:277-282.
4. Bottcher, T., J. Gerber, A. Wellmer, A. V. Smirnov, F. Fakhrjanali, E. Mix, J. Pilz, U. K. Zettl, and R. Nau. 2000. Rifampin reduces production of reactive oxygen species of cerebrospinal fluid phagocytes and hippocampal neuronal apoptosis in experimental Streptococcus pneumoniae meningitis. J. Infect. Dis. 181:2095-2098.
5. Cohen, H. J., and M. E. Chovaniec. 1978. Superoxide generation by digitonin-stimulated guinea-pig granulocytes. J. Clin. Investig. 61:1081-1087.
6. Cross, A. R. 1990. Inhibitors of the leukocyte superoxide generating oxidase: mechanisms of action and methods for their elucidation. Free Radic. Biol. Med. 8:71-93.
7. Demkow, U., W. Malkowska-Zwierz, E. Rogala, E. Skopinska-Rozewska, and Z. Lewandowski. 1995. Effect of antituberculous drugs, isoniazid, pyrazinamide and rifampicin, on chemiluminescence of the human polymorphonuclear leukocytes. Folia Biol. (Prague) 41:257-262.
8. Dietze, R., L. Teixeira, L. M. Rocha, M. Palaci, J. L. Johnson, C. Wells, L. Rose, K. Eisenach, and J. J. Ellner. 2001. Safety and bactericidal activity of rifalazil in patients with pulmonary tuberculosis. Antimicrob. Agents Chemother. 45:1972-1976.
9. Gray, G. D., C. W. Smith, J. C. Hollers, D. E. Chenoweth, V. D. Fiegel, and R. D. Nelson. 1983. Rifampin affects polymorphonuclear leukocyte interactions with bacterial and synthetic chemotaxins but not interactions with serum-derived chemotaxins. Antimicrob. Agents Chemother. 24:777-783.
10. Gray, G. D., and G. M. Ohlmann. 1986. Countergradients of nonchemotactic ligands for N-formylmethionylleucylphenylalanine (FMLP) receptors promote FMLP-induced chemotaxis. Proc. Soc. Exp. Biol. Med. 181:256-262.
11. Heyworth, P. G., A. R. Cross, and J. T. Curnutte. 2003. Chronic granulomatous disease. Curr. Opin. Immunol. 15:578-584.
12. Hoger, P. H., K. Vosbeck, R. Seger, and W. H. Hitzig. 1985. Uptake, intracellular activity, and influence of rifampin on normal function of polymorphonuclear leukocytes. Antimicrob. Agents Chemother. 28:667-674.
13. Hosoe, K., T. Mae, E. Konishi, K. Fujii, K. Yamashita, T. Yamane, T. Hidaka, and T. Ohashi. 1996. Pharmacokinetics of KRM-1648, a new benzoxazinorifamycin, in rats and dogs. Antimicrob. Agents Chemother. 40: 2749-2755.
14. Labro, M.-T. 2000. Interference of antibacterial agents with phagocyte functions: immunomodulation or "immuno-fairy tales"? Clin. Microbiol. Rev. 13:615-650.
15. Labro, M. T. 2005. Antiinflammatory activity of ansamycins. Expert Rev. Anti-lnfect. Ther. 3:91-103.
16. Labro, M. T. 2004. Antibacterial agents and the oxidative burst, p. 85-106. In B. K. Rubin and J. Tamaoki (ed.), Antibiotics as anti-inflammatory and immunomodulatory agents. Birkhäuser Verlag AG, Basel, Switzerland.
17. Labro, M. T., and J. El Benna. 1993. Interaction of antibiotics with the phagocyte oxidative burst, p. 953-964. In E. Faist, J. L. Meakins, and F. W. Schildberg (ed.), Host defense dysfunction in trauma, shock and sepsis. Springer-Verlag, Berlin, Germany.
18. Miesel, R., D. Sanocka, M. Kurpisz, and H. Kröger. 1995. Antiinflammatory effects of NADPH oxidase inhibitors. Inflammation 19:347-362.
19. Myhre, O., J. M. Andersen, H. Aarnes, and F. Fonnum. 2003. Evaluation of the probes 2′,7′-dichlorofluorescein diacetate, luminol, and lucigenin as indicators of reactive species formation. Biochem. Pharmacol. 65:1575-1582.
20. Nielsen, H. 1989. Antibiotics and human monocyte function. II. Phagocytosis and oxidative metabolism. APMIS 97:447-451.
21. Plantin-Carrenard, E., F. Braut-Boucher, M. Bernard, C. Derappe, M. J. Foglietti, and M. Aubery. 2000. Fluorogenic probes applied to the study of induced oxidative stress in the human leukaemia HL 60 cell line. J. Fluoresc. 10:167-176.
22. Roblin, P. M., T. Reznik, A. Kutlin, and M. R. Hammerschlag. 2003. In vitro activities of rifamycin derivatives ABI-1648 (rifalazil, KRM-1648), ABI-1657, and ABI-1131 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae. Antimicrob. Agents Chemother. 47:1135-1136.
23. Roos, D., R. van Bruggen, and C. Meischl. 2003. Oxidative killing of microbes by neutrophils. Microbes Infect. 5:1307-1315.
24. Rose, L. M., M. K. Vasiljev, P. Adams, V. Mizuno, C. Wells, and A. B. Montgomery. 1999. Safety and pharmacokinetics of PA-1648, a new rifamycin in normal volunteers. Am. J. Respir. Crit. Care Med. 159(Suppl.):A495.
25. Rothstein, D. M., A. D. Hartman, M. H. Cynamon, and B. I. Eisenstein. 2003. Development potential of rifalazil. Expert Opin. Investig. Drugs 12: 255-271.
26. Spisani, S., L. Dovigo, G. Corazza, R. Carletti, and S. Traniello. 1982. The effect of rifamycin SV on neutrophil functions in patients with rheumatoid arthritis. Scand. J. Rheumatol. 11:65-69.
27. Spisani, S., S. Traniello, C. Martuccio, O. Rizzuti, and L. Cellai. 1997. Rifamycins inhibit human neutrophil functions: new derivatives with potential antiinflammatory activity. Inflammation 21:391-400.
28. Spisani, S., S. Traniello, A. M. Onori, O. Rizzuti, C. Martuccio, and L. Cellai. 1998. 3-(Carboxyalkylthio) rifamycin S and SV derivatives inhibit human neutrophil functions. Inflammation 22:459-469.
29. Vignais, P. V. 2002. The superoxide-generating NADPH oxidase: structural aspects and activation mechanism. Cell. Mol. Life Sci. 59:1428-1459.
30. Whiteman, M., and B. Halliwell. 1997. Prevention of peroxynitrite- dependent tyrosine titration and inactivation of alpha1 antiproteinase by antibiotics. Free Radic. Res. 26:49-56.
31. Zeis, B. M. 1988. Antimycobacterial drugs and the production of reactive oxidants by polymorphonuclear leucocytes in vitro. Chemotherapy 34:56-60.